Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases

Gray, Simon; Khor, Xiao Ying; Yiannakis, Dennis

doi:10.1136/bcr-2019-230738

Cited by 22 publications

(18 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 38 Primary peritoneal cancer IIIC >2 None BRCA1 Olaparib 22 months Gray et al, 2019. 39 Ovarian cancer IIIC >2 None BRCA1 Niraparib 17 months Favier et al, 2020. 40 Ovarian cancer IIIC – Peritoneum BRCA2 Olaparib 14 months …”

Section: Discussionmentioning

confidence: 99%

Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review

Tao¹,

Cheng²,

Wu³

2020

OTT

View full text Add to dashboard Cite

Brain metastases from epithelial ovarian cancer are very rare with an incidence of only 1–2.5%. Many therapeutic methods such as surgery, irradiation and chemotherapy do produce survival benefits, but the overall outcome remains unsatisfactory. The BRCA (breast cancer susceptibility gene) mutation status seems to be associated with the development of brain metastases from ovarian cancer and these patients may benefit from treatment with PARP (poly ADP ribose polymerase) inhibitors. Here is a case where a Chinese female patient diagnosed with high-grade serous ovarian cancer with brain metastases was detected to have known germline ATM mutation and somatic BRCA2 mutation. The patient underwent whole brain radiotherapy and systemic chemotherapy, commenced niraparib as maintenance treatment and then presented considerable clinical and radiological response.

show abstract

Section: Discussionmentioning

confidence: 99%

Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review

Tao¹,

Cheng²,

Wu³

2020

OTT

View full text Add to dashboard Cite

show abstract

“…Pre-clinical studies have shown how specific PARPi, like niraparib, can cross the blood–brain barrier [ 71 , 72 ] and, in recent years, there have been cases reporting the use of these drugs in this subset of patients: five patients treated with PARPi had BRCA mutation; all of them achieved a progression-free survival of over 10 months [ 73 , 74 , 75 , 76 , 77 ]. Interestingly, a phase II single arm open-label study to evaluate the efficacy of niraparib in patients with BMs is ongoing [NCT04992013].…”

Section: Brcamentioning

confidence: 99%

Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer

Scotto

Borella

Turinetto

et al. 2021

Cells

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is the leading cause of death among women affected by gynaecological malignancies. Most patients show advanced disease at diagnosis (FIGO stage III-IV) and, despite the introduction of new therapeutic options, most women experience relapses. In most cases, recurrence is abdominal-pelvic; however, EOC can occasionally metastasize to distant organs, including the central nervous system. The incidence of brain metastases (BMs) from EOC is low, but it has grown over time; currently, there are no follow-up strategies available. In the last decade, a few biomarkers able to predict the risk of developing BMs from OC or as potential therapeutic targets have been investigated by several authors; to date, none have entered clinical practice. The purpose of this review is to offer a summary on the role of the most relevant predictors of central nervous system (CNS) involvement (hormone receptors; BRCA; MRD1; PD-1/PD-L1) and to highlight possible therapeutic strategies for the management of metastatic brain disease in EOC

show abstract

“…-a 68-year-old woman with BM from high-grade serous OC was treated with Niraparib as maintenance therapy and remained free of disease progression for more than 17 months [120].…”

Section: Parp Inhibitorsmentioning

confidence: 99%

Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis

Borella

Bertero

Morrone

et al. 2020

Cancers

View full text Add to dashboard Cite

With this review, we provide the state of the art concerning brain metastases (BMs) from ovarian cancer (OC), a rare condition. Clinical, pathological, and molecular features, treatment options, and future perspectives are comprehensively discussed. Overall, a diagnosis of high-grade serous OC and an advanced disease stage are common features among patients who develop brain metastases. BRCA1 and BRCA2 gene mutations, as well as the expression of androgen receptors in the primary tumor, are emerging risk and prognostic factors which could allow one to identify categories of patients at greater risk of BMs, who could benefit from a tailored follow-up. Based on present data, a multidisciplinary approach combining surgery, radiotherapy, and chemotherapy seem to be the best approach for patients with good performance status, although the median overall survival (<1 year) remains largely disappointing. Hopefully, novel therapeutic avenues are being explored, like PARP inhibitors and immunotherapy, based on our improved knowledge regarding tumor biology, but further investigation is warranted.

show abstract

Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases

Cited by 22 publications

References 17 publications

<p>Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic <em>BRCA2</em>-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review</p>

<p>Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic <em>BRCA2</em>-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review</p>

Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer

Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis

Contact Info

Product

Resources

About